Evaluation of the Presence of Hereditary and Acquired Thrombophilias in Brazilian Children and Adolescents With Diagnoses of Portal Vein Thrombosis

被引:21
作者
Ferri, Priscila Menezes [1 ]
Ferreira, Alexandre Rodrigues [1 ]
Tavares Fagundes, Eleonora Druve [1 ]
Xavier, Sandra Guerra [2 ]
Ribeiro, Daniel Dias [1 ]
Fernandes, Ana Paula [1 ]
Gomes Borges, Karina Braga [1 ]
Liu, Shinfay Maximilian [2 ]
Barros de Melo, Maria do Carmo [1 ]
Valadares Roquete, Mariza Leitao [1 ]
Penna, Francisco Jose [1 ]
机构
[1] Univ Fed Minas Gerais, Dept Pediat Gastroenterol, Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Dept Clin Pathol & Lab Med, Belo Horizonte, MG, Brazil
关键词
adolescent; child; portal vein; thrombophilia; thrombosis; V-LEIDEN MUTATION; TYROSINE KINASE JAK2; RISK-FACTORS; ESSENTIAL THROMBOCYTHEMIA; PEDIATRIC-PATIENTS; VENOUS THROMBOSIS; JAK2V617F MUTATION; POLYCYTHEMIA-VERA; PROTHROMBIN GENE; PROTEIN-C;
D O I
10.1097/MPG.0b013e318261814d
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: The aim of this study was to describe the prevalence of main hereditary thrombophilias, Janus kinase 2 (JAK2) V617F mutation, antiphospholipid antibody syndrome (APS), and hyperhomocysteinemia in Brazilian children and adolescents diagnosed with portal vein thrombosis (PVT) without associated hepatic disease. Methods: A cross-sectional study was carried out with 32 children with PVT in accompaniment at Hospital das Clinicas of the Universidade Federal de Minas Gerais from January 1990 to July 2011. Laboratory evaluation of thrombophilias was performed from September 2010 to July 2011. Results: Thirty-two patients were evaluated; 59% were boys. Median age at diagnosis was 2.4 years. Mean time of patients' accompaniment was between 4.7 and 5.2 years. The presence of hereditary and acquired thrombophilias occurred in 34.4% of patients, and 9 of them also showed other risk factors in the previous history evaluation. Risk factors were absent in the previous history of 18 patients (56.3%). Two patients showed persistent high titres of anticardiolipin antibodies. Hyperhomocysteinemia was not observed. One patient was heterozygous for factor V Leiden and prothrombin G20210A mutation (3.1%). Eleven patients (34.4%) showed heterozygous methylenetetrahydrofolate reductase (MTHFR) C677T, and no patient had the JAK2V617F mutation. Conclusions: Even after investigation of main hereditary and acquired thrombophilia, PVT remains without apparent cause in most patients. Nevertheless, association of local and systemic risk factors seems to be important also in the pediatric age group. Therefore, despite the low prevalence, a complete investigation, which includes both hereditary and acquired thrombophilias, may be necessary.
引用
收藏
页码:599 / 604
页数:6
相关论文
共 50 条
  • [1] PORTAL OBSTRUCTION IN CHILDREN .1. CLINICAL INVESTIGATION AND HEMORRHAGE RISK
    ALVAREZ, F
    BERNARD, O
    BRUNELLE, F
    HADCHOUEL, P
    ODIEVRE, M
    ALAGILLE, D
    [J]. JOURNAL OF PEDIATRICS, 1983, 103 (05) : 696 - 702
  • [2] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [3] Etiology and consequences of thrombosis in abdominal vessels
    Bayraktar, Yusuf
    Harmanci, Ozgur
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (08) : 1165 - 1174
  • [4] Portal Vein Thrombosis and Budd-Chiari Syndrome
    Bittencourt, Paulo Lisboa
    Couto, Claudia Alves
    Ribeiro, Daniel Dias
    [J]. CLINICS IN LIVER DISEASE, 2009, 13 (01) : 127 - +
  • [5] Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia
    Buchel, O
    Roskams, T
    Van Damme, B
    Nevens, F
    Pirenne, J
    Fevery, J
    [J]. GUT, 2005, 54 (07) : 1021 - 1023
  • [6] Portal biliopathy
    Chandra, R
    Kapoor, D
    Tharakan, A
    Chaudhary, A
    Sarin, SK
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (10) : 1086 - 1092
  • [7] The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
    Colaizzo, D.
    Amitrano, L.
    Tiscia, G. L.
    Scenna, G.
    Grandone, E.
    Guardascione, M. A.
    Brancaccio, V.
    Margaglione, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (01) : 55 - 61
  • [8] Cause of portal or hepatic venous thrombosis in adults:: The role of multiple concurrent factors
    Denninger, MH
    Chaït, Y
    Casadevall, N
    Hillaire, S
    Guillin, MC
    Bezeaud, A
    Erlinger, S
    Briere, J
    Valla, D
    [J]. HEPATOLOGY, 2000, 31 (03) : 587 - 591
  • [9] JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
    Dentali, Francesco
    Squizzato, Alessandro
    Brivio, Lorenza
    Appio, Lorena
    Campiotti, Leonardo
    Crowther, Mark
    Grandi, Anna Maria
    Ageno, Walter
    [J]. BLOOD, 2009, 113 (22) : 5617 - 5623
  • [10] Protein C, protein S and antithrombin III in children with portal vein obstruction
    Dubuisson, C
    BoyerNeumann, C
    Wolf, M
    Meyer, D
    Bernard, O
    [J]. JOURNAL OF HEPATOLOGY, 1997, 27 (01) : 132 - 135